Eledon Pharmaceuticals, Inc. reported a net loss of $45.6 million for the fiscal year ending December 31, 2025, compared to a net loss of $36.2 million in the previous year, marking a 26% increase in losses. The company's total operating expenses rose to $83.3 million, an 18% increase from $70.6 million in 2024. This increase was primarily driven by a 28% rise in research and development expenses, which reached $66.3 million, largely due to heightened activities in clinical trials for its lead product candidate, tegoprubart, particularly in kidney transplantation programs. General and administrative expenses decreased by 9% to $17.0 million, reflecting a reduction in stock-based compensation.
Eledon continues to focus on the development of tegoprubart, an anti-CD40L antibody aimed at preventing organ transplant rejection and treating amyotrophic lateral sclerosis (ALS). The company has prioritized its kidney transplantation programs, discontinuing its islet cell transplantation and IgA nephropathy programs due to resource allocation decisions. As of December 31, 2025, Eledon had cash and cash equivalents totaling $133.3 million, which it believes will be sufficient to fund operations for at least the next 12 months. However, the company anticipates needing additional capital to continue its clinical development efforts, particularly for ALS, which is currently on hold pending financing.
In terms of strategic developments, Eledon has engaged in several financing activities, including a 2025 underwritten offering that raised approximately $53.6 million in net proceeds. The company has also entered into various securities purchase agreements, which have provided significant capital to support its operations. As of the end of 2025, Eledon had 33 employees, all full-time, and has not experienced significant changes in its workforce.
Looking ahead, Eledon plans to seek guidance from the FDA regarding the design of a potential Phase 3 clinical trial for tegoprubart in kidney transplantation. The company is also exploring opportunities in xenotransplantation and is collaborating with eGenesis, Inc. to support preclinical and clinical studies in this area. Despite the challenges posed by the need for additional financing and the competitive landscape, Eledon remains committed to advancing its clinical programs and optimizing the commercial potential of its product candidates.
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals is a biotech company focused on developing immunology-based therapies targeting the CD40 Ligand pathway. Its lead candidate, tegoprubart, is an anti-CD40L antibody designed to prevent organ transplant rejection, treat autoimmune diseases, and address neurodegenerative conditions like ALS. The company advances its products through clinical trials, leveraging proprietary IP, and collaborates with research institutions to improve transplant outcomes and neuroinflammation management.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.